×
About 1,665 results

ALLMedicine™ Intracranial Tumors Center

Research & Reviews  614 results

Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know.
https://doi.org/10.1148/rg.210235
Radiographics : a Review Publication of the Radiological ... Wang MX, Dillman JR et. al.

Jun 25th, 2022 - Neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) are autosomal dominant inherited neurocutaneous disorders or phakomatoses secondary to mutations in the NF1 and NF2 tumor suppressor genes, respectively. Although they share a commo...

Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of ...
https://doi.org/10.2174/1389200223666220616125524
Current Drug Metabolism; Sahoo RK, Gupta T et. al.

Jun 18th, 2022 - Gliomas are the most prevailing intracranial tumors, which account for approximately 36% of the primary brain tumors of glial cells. Glioblastoma multiforme (GBM) possesses a higher degree of malignancy among different gliomas. The blood-brain bar...

Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas...
https://doi.org/10.1038/s41379-022-01113-8
Modern Pathology : an Official Journal of the United Stat... Ferreyra Vega S, Wenger A et. al.

Jun 15th, 2022 - Adult-type diffuse gliomas and meningiomas are the most common primary intracranial tumors of the central nervous system. DNA methylation profiling is a novel diagnostic technique increasingly used also in the clinic. Although molecular heterogene...

Hydrogen Proton Magnetic Resonance Spectroscopy (MRS) in Differential Diagnosis of Intr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132669
Contrast Media & Molecular Imaging; Wang L, Chen G et. al.

Jun 4th, 2022 - Meningioma, glioma, and metastases are the most common intracranial tumors in clinical practice. In order to improve the prognosis of patients, timely diagnosis and early treatment are crucial. Hydrogen proton magnetic resonance spectroscopy (1H-M...

The road-map for establishment of a prognostic molecular marker panel in glioma using l...
https://doi.org/10.1007/s12094-022-02833-8 10.1001/jamaoncol.2018.1789 10.1007/s11060-015-1798-x 10.1186/s12885-016-2131-6] 10.3389/fphar.2018.00879] 10.1186/s12885-017-3909-x] 10.1093/annonc/mdu050 10.1186/s13014-016-0702-y] 10.1186/s13244-020-00888-1] 10.1007/s00401-016-1545-1 10.1038/d41586-018-06711-8] 10.1007/s11864-018-0559-4] 10.1007/s11060-015-1829-7 10.3171/2016.11.JNS161187 10.3171/2015.1.FOCUS14755.] 10.3390/cells8080863] 10.3171/2017.3.JNS162280] 10.1007/s40291-020-00449-8] 10.1016/j.immuni.2019.06.025 10.1080/2162402X.2020.1779990] 10.1016/j.molcel.2010.09.022 10.1038/nri2607] 10.1155/2013/914104] 10.3892/ol.2018.9227 10.4103/2347-8659.139717 10.1016/j.it.2014.12.008.] 10.3389/fimmu.2016.00604] 10.7150/jca.16415 10.1007/s11060-018-2803-y] 10.1155/2013/979748 10.1371/journal.pone.0137524 10.3906/sag-1611-77] 10.1016/j.ebiom.2018.06.014] 10.1371/journal.pone.0112945] 10.1016/j.jocn.2015.06.018 10.4172/2471-9552.1000125 10.1038/ncb2621] 10.1074/jbc.M115.681619 10.1093/nar/gkz584 10.1038/bjc.2014.538 10.1007/s11060-017-2578-6 10.1158/1078-0432.CCR-20-3083 10.3390/biomedicines5030036 10.3389/fnagi.2019.00231 10.3892/or.2018.6896 10.1186/s12885-019-5287-z 10.1586/ern.13.42 10.1007/978-3-030-14366-4_1 10.1155/2016/7849890] 10.1016/j.ccr.2009.12.049 10.1002/1873-3468.13084 10.3390/ijms20235950 10.1016/j.brainres.2011.01.105 10.1089/ars.2008.2400 10.1038/s41389-017-0011-9 10.1016/j.cell.2011.06.006 10.1038/nrc3064 10.3892/ol.2016.4952] 10.1093/neuonc/now258 10.3390/ijms20225794 10.4172/2155-9899.1000264 10.1007/s11060-017-2600-z 10.3109/09553002.2014.916841 10.1155/2016/6809105 10.1007/s12035-020-01892-8 10.4161/cam.3.2.7910 10.1080/20013078.2017.1359479 10.3892/ol.2017.6221 10.1177/030089160709300308 10.1007/s13277-015-4742-y 10.1155/2013/417413 10.1186/s12943-017-0721-9 10.3171/2009.5.JNS081074 10.1371/journal.pone.0192395 10.1515/revneuro-2020-0062 10.3390/cancers14010238 10.2147/MNM.S105123 10.1080/13102818.2019.1626282 10.1016/s0304-3835(99)00255-4 10.1007/s10238-009-0040-6
Clinical & Translational Oncology : Official Publication ... Shrivastava R, Gandhi P et. al.

Jun 3rd, 2022 - Gliomas are primary intracranial tumors with defined molecular markers available for precise diagnosis. The prognosis of glioma is bleak as there is an overlook of the dynamic crosstalk between tumor cells and components of the microenvironment. H...

see more →

Clinicaltrials.gov  38 results

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04657146

Jun 2nd, 2022 - The investigators' recent studies show that large numbers of T cells in patients and mice with intracranial tumors are sequestered in bone marrow. This phenomenon mysteriously confines a pool of functional, naïve T cells with anti-tumor capacity t...

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
https://clinicaltrials.gov/ct2/show/NCT04278118

May 25th, 2022 - PRIMARY OBJECTIVE: I. To report 3 year local tumor control of moderately hypofractionated proton or photon therapy for benign intracranial tumors. SECONDARY OBJECTIVES: I. To demonstrate feasibility of moderate hypofractionation pencil beam scanni...

Analysis of Selective Cerebrovascular Distribution With FDCT in the Angiosuite
https://clinicaltrials.gov/ct2/show/NCT03916133

May 17th, 2022 - The aim of this study is to evaluate the clinical feasibility of the angiographic Flat Detector CT perfusion imaging (6s PBV) technique. The investigators will examine the specific vessel distribution of patients with steno-occlusive disease, trea...

PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI
https://clinicaltrials.gov/ct2/show/NCT04638478

Apr 12th, 2022 - Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33% of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors. The 10-year survival rate is 72%. A variety of treatment opti...

Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
https://clinicaltrials.gov/ct2/show/NCT04044937

Apr 5th, 2022 - PRIMARY OBJECTIVES: I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1. II. To determine if FET PET can accurately differ...

see more →

News  14 results

Making Progress Against the Blood-Brain Barrier
https://www.onclive.com/view/making-progress-against-the-blood-brain-barrier

Jan 31st, 2022 - Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier (BBB), a highly restrictive interface between the bloodstream and the brain that prevents most dru...

'Phantom Odors' a Common but Under-Reported Toxicity of Radiation Therapy
https://www.medscape.com/viewarticle/961865

Nov 1st, 2021 - NEW YORK (Reuters Health) - Patients who undergo proton-beam radiation therapy to tumors located in or adjacent to the olfactory region may develop phantosmia - the perception of a foul-smelling odor for which there is no external stimulus. "Phant...

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging
https://www.onclive.com/view/advanced-3d-mri-technology-marks-a-leap-forward-in-glioblastoma-imaging

Oct 6th, 2021 - Hui-Kuo Shu, MD, PhD Associate Professor Although advances have been made in imaging techniques for patients with glioblastoma multiforme (GBM), new tools are needed to supplement standard imaging sequences. Researchers at the Winship Cancer...

A Pilot With Electrical Pain in the Face
https://www.mdedge.com/fedprac/article/242807/pain/pilot-electrical-pain-face
LT John M. Curnes, MD, MC, USN

Jul 12th, 2021 - A 25-year-old male student pilot presented to his flight surgeon in Corpus Christi, Texas, with a 1-year history of episodic left-sided facial pain. He described the pain as electric-like with subsequent tingling sensation.

The Man Behind the Brain: Harvey Cushing's Legacy
https://www.staging.medscape.com/viewarticle/936873

Sep 9th, 2020 - A physician is obligated to consider more than a diseased organ, more than even the whole man — he must view the man in his world. –Harvey Williams Cushing A well-known photo of Harvey Cushing, taken by a friend in Switzerland. Source: Wikimedia C...

see more →